WO2005092277A1 - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- WO2005092277A1 WO2005092277A1 PCT/EP2005/002879 EP2005002879W WO2005092277A1 WO 2005092277 A1 WO2005092277 A1 WO 2005092277A1 EP 2005002879 W EP2005002879 W EP 2005002879W WO 2005092277 A1 WO2005092277 A1 WO 2005092277A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oral composition
- betaine
- anionic surfactant
- composition according
- oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/36—Carboxylic acids; Salts or anhydrides thereof
- A61K8/365—Hydroxycarboxylic acids; Ketocarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
- A61K8/463—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfuric acid derivatives, e.g. sodium lauryl sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
Definitions
- the present invention relates to an oral composition according to the preamble of claim 1.
- the object of the present invention is to provide an oral composition which improves the delivery of sparingly soluble zinc citrate from an oral composition comprising an anionic surfactant.
- WO02/026203 discloses an oral composition comprising cocoacylamidopropyl betaine and sodium lauryl sulphate.
- the composition also comprises zinc sulphate, a water soluble zinc salt.
- the present invention provides an oral composition according to claim 1.
- the composition comprises the betaine derivative and the anionic surfactant in a weight ratio of from 0.95:1 to 1.05:1.
- the oral care composition according to the invention comprises from 0.001 to 5% by weight zinc citrate, more preferably from 0.5 to 3.0% by weight.
- Suitable anionic surfactants are, for example, sodium alkyl sulfates containing 12 to 18 carbon atoms in the alkyl group.
- Other suitable anionic surfactants are alkali metal salts, preferably sodium salts of alkyl polyglycol ether sulfate containing 12 to 16 carbon atoms in the linear alkyl group and 2 to 6 glycol ether groups in the molecule, of linear alkane (C 12-18) sulfonate, • of sulfosuccinic acid onoalkyl (C 12-18 ) esters, of .suJLfated fatty acid onoglycerides, sulfated fatty acicTalkanolamides, sulfoacetic acid alkyl (C 12-16 ' ).
- Suitable betaine surfactants include cocoalkyl betaine or cocoamidopropyl betaine.
- the antimicrobial agent is present in an amount of from 0.01 to 5% by weight of the composition, more preferably from 0.5 to 3% by weight..
- composition according to the invention comprise further ingredients which are common in the art, such as:
- antimicrobial agents e.g. Triclosan, chlorhexidine, sanguinarine extract, metronidazole, quaternary ammonium compounds, such as cetylpyridinium chloride; bis-guanides, such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; halogenated bisphenolic compounds, such as 2,2' methylenebis- (4-chloro-6-bromophenol) , and the alkyl parabens such as n-octyl paraben and analogues thereof;
- Triclosan chlorhexidine, sanguinarine extract, metronidazole, quaternary ammonium compounds, such as cetylpyridinium chloride
- bis-guanides such as chlorhexidine digluconate, hexetidine, octenidine, alexidine
- halogenated bisphenolic compounds such as 2,2' methylenebis- (4-chloro-6-bromophenol)
- anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc.
- anti-caries agents such as sodium- and stannous fluoride, aminefluorides, sodium monofluorophosphate, sodium trimeta phosphate and casein;
- plaque buffers such as urea, calcium lactate, calcium glycerophosphate and strontium polyacrylates
- vitamins such as Vitamins A, C and E;
- desensitising agents e.g. potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate and strontium salts;
- anti-calculus agents e.g. alkali-metal pyrophosphates, hypophosphite-containing polymers, organic phosphonates and phosphocitrates etc.;
- biomolecules e.g. bacteriocins, antibodies, enzymes, etc.
- flavours e.g. peppermint and spearmint oils
- proteinaceous materials such as collagen
- pH-adjusting agents sweetening agents
- pharmaceutically acceptable carriers e.g. starch, sucrose, water or water/alcohol systems etc.;
- surfactants such as anionic, nonionic, cationic and • zwitterionic or amphoteric surfactants
- particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, tri etaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between 3 and 60% by weight of the oral care composition.
- polymeric compounds which can enhance" the delivery of active ingredients such as antimicrobial agents can also be included;
- bleaching agents such as peroxy compounds e.g. potassium peroxydiphosphate, effervescing systems such as sodium bicarbonate/citric acid systems, colour change systems, and so on.
- Liposomes may also be used to improve delivery or stability of active ingredients.
- the oral compositions may be in any form common in the art, e.g. toothpaste, gel, mousse, gum, cream, etc. and may also be formulated into systems for use in dual-compartment type dispensers.
- the toothpaste according to the invention is made by standard processes.
- An example of an 'oral composition according to the invention is found in the Example. It is made using processes known to the person skilled in the art.
Abstract
An oral composition comprising zinc citrate, a betaine derivative and an anionic surfactant, characterised in that the composition comprises the betaine derivative and the anionic surfactant in a weight ratio of from 0.5:1 to 2:1.
Description
ORAL COMPOSITION
The present invention relates to an oral composition according to the preamble of claim 1.
The object of the present invention is to provide an oral composition which improves the delivery of sparingly soluble zinc citrate from an oral composition comprising an anionic surfactant.
WO02/026203 (Henkel) discloses an oral composition comprising cocoacylamidopropyl betaine and sodium lauryl sulphate. The composition also comprises zinc sulphate, a water soluble zinc salt.
Accordingly, the present invention provides an oral composition according to claim 1.
Preferably, the composition comprises the betaine derivative and the anionic surfactant in a weight ratio of from 0.95:1 to 1.05:1.
Preferably, the oral care composition according to the invention comprises from 0.001 to 5% by weight zinc citrate, more preferably from 0.5 to 3.0% by weight.
Suitable anionic surfactants are, for example, sodium alkyl sulfates containing 12 to 18 carbon atoms in the alkyl group. Other suitable anionic surfactants are alkali metal salts, preferably sodium salts of alkyl polyglycol ether sulfate containing 12 to 16 carbon atoms in the linear alkyl
group and 2 to 6 glycol ether groups in the molecule, of linear alkane (C 12-18) sulfonate, • of sulfosuccinic acid onoalkyl (C 12-18 ) esters, of .suJLfated fatty acid onoglycerides, sulfated fatty acicTalkanolamides, sulfoacetic acid alkyl (C 12-16' ).* esters, acyl sarcosines, acyl taurides and acyl isothionates containing 8 to 18 carbon atoms in the acyl group.
Suitable betaine surfactants include cocoalkyl betaine or cocoamidopropyl betaine.
Preferably the antimicrobial agent is present in an amount of from 0.01 to 5% by weight of the composition, more preferably from 0.5 to 3% by weight..
The oral composition according to the invention comprise further ingredients which are common in the art, such as:
antimicrobial agents, e.g. Triclosan, chlorhexidine, sanguinarine extract, metronidazole, quaternary ammonium compounds, such as cetylpyridinium chloride; bis-guanides, such as chlorhexidine digluconate, hexetidine, octenidine, alexidine; halogenated bisphenolic compounds, such as 2,2' methylenebis- (4-chloro-6-bromophenol) , and the alkyl parabens such as n-octyl paraben and analogues thereof;
anti-inflammatory agents such as ibuprofen, flurbiprofen, aspirin, indomethacin etc.;
anti-caries agents such as sodium- and stannous fluoride, aminefluorides, sodium monofluorophosphate, sodium trimeta phosphate and casein;
plaque buffers such as urea, calcium lactate, calcium glycerophosphate and strontium polyacrylates;
vitamins such as Vitamins A, C and E;
plant extracts;
desensitising agents, e.g. potassium citrate, potassium chloride, potassium tartrate, potassium bicarbonate, potassium oxalate, potassium nitrate and strontium salts;
anti-calculus agents, e.g. alkali-metal pyrophosphates, hypophosphite-containing polymers, organic phosphonates and phosphocitrates etc.;
biomolecules, e.g. bacteriocins, antibodies, enzymes, etc.; flavours, e.g. peppermint and spearmint oils;
proteinaceous materials such as collagen;
preservatives;
opacifying agents;
colouring agents;
pH-adjusting agents;
sweetening agents;
pharmaceutically acceptable carriers, e.g. starch, sucrose, water or water/alcohol systems etc.;
surfactants, such as anionic, nonionic, cationic and • zwitterionic or amphoteric surfactants;
particulate abrasive materials such as silicas, aluminas, calcium carbonates, dicalciumphosphates, calcium pyrophosphates, hydroxyapatites, tri etaphosphates, insoluble hexametaphosphates and so on, including agglomerated particulate abrasive materials, usually in amounts between 3 and 60% by weight of the oral care composition.
polymeric compounds which can enhance" the delivery of active ingredients such as antimicrobial agents can also be included;
buffers and salts to buffer the pH and ionic strength of the oral care composition; and
other optional ingredients that may be included are e.g. bleaching agents such as peroxy compounds e.g. potassium peroxydiphosphate, effervescing systems such as sodium bicarbonate/citric acid systems, colour change systems, and so on.
Liposomes may also be used to improve delivery or stability of active ingredients.
The oral compositions may be in any form common in the art, e.g. toothpaste, gel, mousse, gum, cream, etc. and may also be formulated into systems for use in dual-compartment type dispensers.
The toothpaste according to the invention is made by standard processes. An example of an 'oral composition according to the invention is found in the Example. It is made using processes known to the person skilled in the art.
EXAMPLE
Claims
1. An oral composition comprising zinc citrate, a betaine surfactant and an anionic surfactant, characterised in that the composition comprises the betaine derivative and the anionic surfactant in a weight ratio of from 0.5:1 to 2:1.
2. An oral composition according to claim 1 wherein the betaine surfactant is cocoamidopropyl betaine.
3. An oral composition according to any preceding claim wherein the anionic surfactant is sodium lauryl sulphate.
4. An oral composition according to ^any preceding claim wherein the composition comprises from 0.5 to 1.3% by weight anionic surfactant.
5. An oral composition according to any preceding claim wherein the composition comprises from 0.5 to 1.3% by weight betaine surfactant.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04251741 | 2004-03-25 | ||
| EP04251741.7 | 2004-03-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2005092277A1 true WO2005092277A1 (en) | 2005-10-06 |
Family
ID=34930238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/002879 WO2005092277A1 (en) | 2004-03-25 | 2005-03-16 | Oral composition |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2005092277A1 (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007076444A3 (en) * | 2005-12-21 | 2007-08-16 | Colgate Palmolive Co | Improved oral compositions comprising zinc citrate and/or tocopherol agents |
| JP2014108948A (en) * | 2012-12-03 | 2014-06-12 | Lion Corp | Liquid composition for oral cavity |
| US9968803B2 (en) | 2009-10-29 | 2018-05-15 | Colgate-Palmolive Company | Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy |
| WO2021062623A1 (en) * | 2019-09-30 | 2021-04-08 | The Procter & Gamble Company | Dentifrice compositions for treatment of dental biofilm |
| WO2021063384A1 (en) * | 2019-09-30 | 2021-04-08 | The Procter & Gamble Company | Dentifrice compositions comprising bicarbonate salt and neutral amino acid |
| US11419799B2 (en) | 2019-09-30 | 2022-08-23 | The Procter & Gamble Company | Oral care compositions comprising stannous ion source, neutral amino acid, and polyphosphate |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001173A1 (en) * | 1993-07-01 | 1995-01-12 | Unilever N.V. | Amphoteric surfactant for the treatment of aphthous ulcers |
| WO1996029049A1 (en) * | 1995-03-20 | 1996-09-26 | Unilever Plc | Liquid cleansing formulations |
| US6169118B1 (en) * | 1998-11-12 | 2001-01-02 | Block Drug Company, Inc. | Flavor blend for masking unpleasant taste of zinc compounds |
| WO2002026203A2 (en) * | 2000-09-27 | 2002-04-04 | Henkel Kommanditgesellschaft Auf Aktien | Dental cleaning agents |
-
2005
- 2005-03-16 WO PCT/EP2005/002879 patent/WO2005092277A1/en active Application Filing
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1995001173A1 (en) * | 1993-07-01 | 1995-01-12 | Unilever N.V. | Amphoteric surfactant for the treatment of aphthous ulcers |
| WO1996029049A1 (en) * | 1995-03-20 | 1996-09-26 | Unilever Plc | Liquid cleansing formulations |
| US6169118B1 (en) * | 1998-11-12 | 2001-01-02 | Block Drug Company, Inc. | Flavor blend for masking unpleasant taste of zinc compounds |
| WO2002026203A2 (en) * | 2000-09-27 | 2002-04-04 | Henkel Kommanditgesellschaft Auf Aktien | Dental cleaning agents |
| DE10047760A1 (en) * | 2000-09-27 | 2002-04-11 | Henkel Kgaa | Dentifrice |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007076444A3 (en) * | 2005-12-21 | 2007-08-16 | Colgate Palmolive Co | Improved oral compositions comprising zinc citrate and/or tocopherol agents |
| AU2006330508B2 (en) * | 2005-12-21 | 2010-02-25 | Colgate-Palmolive Company | Improved oral compositions comprising zinc citrate and/or tocopherol agents |
| AU2010202023B2 (en) * | 2005-12-21 | 2012-03-01 | Colgate-Palmolive Company | Improved oral compositions comprising zinc citrate and/or tocopherol agents |
| US11147992B2 (en) | 2009-10-29 | 2021-10-19 | Colgate-Palmolive Company | Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy |
| US9968803B2 (en) | 2009-10-29 | 2018-05-15 | Colgate-Palmolive Company | Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy |
| US10668306B2 (en) | 2009-10-29 | 2020-06-02 | Colgate-Palmolive Company | Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy |
| US11285342B2 (en) | 2009-10-29 | 2022-03-29 | Colgate-Palmolive Company | Low water stannous fluoride plus zinc citrate dentifrice with improved stability, rheology, and efficacy |
| JP2014108948A (en) * | 2012-12-03 | 2014-06-12 | Lion Corp | Liquid composition for oral cavity |
| WO2021062623A1 (en) * | 2019-09-30 | 2021-04-08 | The Procter & Gamble Company | Dentifrice compositions for treatment of dental biofilm |
| WO2021063384A1 (en) * | 2019-09-30 | 2021-04-08 | The Procter & Gamble Company | Dentifrice compositions comprising bicarbonate salt and neutral amino acid |
| CN114449995A (en) * | 2019-09-30 | 2022-05-06 | 宝洁公司 | Dentifrice composition comprising bicarbonate salt and neutral amino acid |
| US11419799B2 (en) | 2019-09-30 | 2022-08-23 | The Procter & Gamble Company | Oral care compositions comprising stannous ion source, neutral amino acid, and polyphosphate |
| JP2022548798A (en) * | 2019-09-30 | 2022-11-21 | ザ プロクター アンド ギャンブル カンパニー | Dentifrice composition for treatment of dental biofilm |
| JP2022550527A (en) * | 2019-09-30 | 2022-12-02 | ザ プロクター アンド ギャンブル カンパニー | Dentifrice composition containing bicarbonate and neutral amino acid |
| US11813343B2 (en) | 2019-09-30 | 2023-11-14 | The Procter & Gamble Company | Dentifrice compositions for treatment of dental biofilm |
| JP7414973B2 (en) | 2019-09-30 | 2024-01-16 | ザ プロクター アンド ギャンブル カンパニー | Dentifrice composition for the treatment of dental biofilms |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6475472B2 (en) | Oral bleaching composition | |
| JP3142543B2 (en) | How to remineralize teeth | |
| WO2005092277A1 (en) | Oral composition | |
| WO2008145475A1 (en) | Oral care composition | |
| WO2006050777A1 (en) | Toothpaste composition | |
| WO2006012977A1 (en) | Composition | |
| EP1183006B1 (en) | Oral composition containing perlite | |
| EP1263401B1 (en) | Oral composition comprising 2'-hydroxypropiophenone | |
| WO2000062750A1 (en) | Oral care composition | |
| US20050063921A1 (en) | Oral composition | |
| US6602491B2 (en) | Composition containing alkylhydroxybenzoates | |
| US20030068283A1 (en) | Composition | |
| US20050063920A1 (en) | Oral composition | |
| US20030068282A1 (en) | Composition | |
| US20030215403A1 (en) | Oral composition | |
| US20050063919A1 (en) | Oral composition | |
| US6436372B2 (en) | Oral composition with abrasive mixture of chalk and carbide | |
| US20100226865A1 (en) | Toothpaste composition | |
| WO2001085114A1 (en) | Oral composition | |
| WO2005027862A1 (en) | Oral composition comprising a copolymer comprising cationic and anionic or neutral comonomers | |
| GB2395433A (en) | Oral compositions comprising a halogenated hydroxydiphenyl ether, eg triclosan, and a delivery enhancing agent, eg a parahydroxybenzoate | |
| WO2006005420A1 (en) | Tooth whitening composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
| 122 | Ep: pct application non-entry in european phase |